Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy.
Young KH, Baird JR, Savage T, Cottam B, Friedman D, Bambina S, Messenheimer DJ, Fox B, Newell P, Bahjat KS, Gough MJ, Crittenden MR. · 2016
Read Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy. by Young KH, Baird JR, Savage T, Cottam B, Friedman D, Bambina S, Messenheimer DJ, Fox B, Newell P, Bahjat KS, Gough MJ, Crittenden MR. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4900555.txt.
Description
Kristina H. Young and co-authors showed in 2016 that timing decides how well immune drugs pair with radiation in mouse tumors. Reports of striking joint effects had launched many trials, but the best order was unsettled. Tumors got a single strong radiation dose plus one of two immune antibodies, given at varied times around the radiation.
An antibody against CTLA4 worked best before radiation, partly by draining regulatory T cells first. An OX40-boosting antibody worked best one day after, when tumor pieces are shown to immune cells most. Using both sweet spots in a breast tumor model cured tumors. When is as much a drug trait as which, the study shows.
Catalog record
| CREATOR | Young KH, Baird JR, Savage T, Cottam B, Friedman D, Bambina S, Messenheimer DJ, Fox B, Newell P, Bahjat KS, Gough MJ, Crittenden MR. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |